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Incorporating pharmacodynamic
considerations into caffeine therapeutic
drug monitoring in preterm neonates
Tian Yu1, Alfred H. Balch1, Robert M. Ward2, E. Kent Korgenski3 and Catherine M. T. Sherwin1*
Abstract
Background: This study sought to assess the pharmacokinetic and pharmacodynamic relationships of caffeine
citrate therapy in preterm neonates who had therapeutic drug monitoring (TDM) in the post-extubation period.
Methods: A retrospective observational study was conducted in preterm neonates who received caffeine citrate
therapy for apnea of prematurity and had TDM done in the post-extubation period between January 2006 and
October 2011. The relationships between pharmacodynamic effects (heart rate, respiratory rate, episodes of apnea,
adverse events) and caffeine serum concentrations were explored.
Results: A total of 177 blood samples were obtained from 115 preterm neonates with a median (range) gestational
age of 29 (24 – 33) weeks and birth weight of 1230 (607 – 2304) kg. Caffeine citrate therapy was initiated at a median
(interquartile range) postnatal age of 1 (1 – 3) day and TDM was performed at a postnatal age of 15 (10 – 24) days. No
direct correlations were found between respiratory rate or apneic episodes and caffeine serum concentrations;
however, heart rate and caffeine serum concentrations were significantly correlated (p < 0.05). Dosing regimen of 40/
5 mg/kg q12h (loading dose/maintenance dose, time interval) led to similar endotracheal re-intubation rate but
increased percentage of patients experiencing tachycardia compared to the standard regimen of 20/5 mg/kg q24h
(44.7 % vs 10.2 %, p < 0.001).
Conclusion: Based on this retrospective study, no correlation between episodes of apnea and caffeine serum
concentrations was found in neonates who had TDM of caffeine citrate therapy in the post-extubation period, whereas
a significant association between tachycardia and concentrations existed. Notwithstanding the absence of severe
adverse reactions, TDM should be considered in critically ill neonates with unexplained adverse effects, such as
tachycardia.
Keywords: Caffeine, Neonate, Pharmacodynamics, Therapeutic drug monitoring
Background
Caffeine citrate is the first-line therapy for treatment of
apnea of prematurity [1, 2]. The standard dosing regi-
men, approved by FDA in 1999 [3], is an intravenous
loading dose of 20 mg/kg caffeine citrate followed by a
maintenance dose of 5 mg/kg daily. Other dosing regi-
mens exist, contingent upon the neonatologist’s decision
based on the neonate’s disease status. The therapeutic
range of 5 – 20 mg/L has been used to guide dosing in
neonates and has its origin in early works by J. V. Ar-
anda et al., which reported that optimizing ventilatory
drive and control of apnea without toxicity were achiev-
able with caffeine serum concentrations within this
range [4]. Clinical signs of toxicity have been observed
with caffeine serum concentrations above 40 mg/L [5].
However, therapeutic drug monitoring (TDM) is not
routinely performed due to its benign safety profile
when standard dosing is used [6, 7]. Since TDM usually
requires blood sampling by heel prick and can contrib-
ute to anemia, it is important to understand if TDM is
necessary during caffeine citrate therapy, especially with* Correspondence: Catherine.Sherwin@hsc.utah.edu1Division of Clinical Pharmacology, School of Medicine, University of Utah,
295 Chipeta Way, Suite 1C310, Salt Lake City, UT 84108, USA
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varied dosing regimens other than the FDA approved
regimen.
Several studies did not support the practice of routine
TDM of caffeine citrate therapy or indicated higher
upper bound of therapeutic range (>20 mg/L) in preterm
neonates [8–10]. An observational study of 101 preterm ne-
onates revealed that standard maintenance dose led to
serum concentrations within the recommended range (5 –
20 mg/L) independent of gestational age (GA), which also
held true for patients with concomitant renal or hepatic
dysfunction [8]. A prospective study reported that caffeine
serum concentrations from standard dosing were in a safe
and therapeutic range of 11 – 33 mg/L by 14 postnatal days
and were independent of neonatal demographics including
GA, postmenstrual age (PMA), and weight, suggesting that
routine TDM was not necessary without clinical signs of
apnea or toxicity [9]. A population pharmacokinetic (PK)
study showed that the inter-occasion (day-to-day) variabil-
ity of caffeine clearance was twice the inter-individual vari-
ability in preterm neonates, which implied that adjusting a
maintenance dose based on previous serum concentrations
of the individual neonate was not effective due to the
marked day-to-day randomness in clearance [10]. Gal sug-
gested that the therapeutic concentrations could range
from 10 to 40 mg/L and the likelihood of response and tox-
icity were specific to each individual [11, 12].
Our study examined cardiovascular/respiratory effects
including heart rate, respiratory rate, episodes of apnea,
and adverse events as major pharmacodynamic (PD) pa-
rameters and delineated their association with caffeine
serum concentrations in preterm neonates. Clinical in-
terventions and adverse events were also compared
among various dosing regimens to illustrate the aggre-
gated clinical outcomes resulting from different caffeine
exposures. The aim of this study was to find the rela-
tionship between PD responses and caffeine serum con-
centrations to inform the use of TDM in neonates. This
retrospective study was conducted to serve as a prelim-
inary work for a future prospective study on caffeine cit-
rate dosing regimen optimization in preterm neonates.
Methods
Study design
This retrospective observational study consisted of pre-
term neonates who received caffeine citrate for apnea of
prematurity at 8 sites of Intermountain Healthcare Sys-
tem in Utah (Utah Valley Hospital, Intermountain Med-
ical Center, McKay-Dee Hospital, Primary Children’s
Hospital, Dixie Regional Hospital, Latter-day Saints Hos-
pital, American Fork Hospital, Logan Regional Hospital)
between January 2006 and October 2011. Neonates who
had been previously ventilated at birth, received at least
1 dose of intravenous caffeine citrate within 28 days of
postnatal age (PNA), and had at least 1 blood sample
taken for caffeine concentration measurement were in-
cluded for analysis. Patients were excluded if they re-
ceived caffeine citrate therapy for other indications
(neonatal respiratory distress syndrome), apnea due to
other causes (confirmed sepsis or pneumonia, diagnosed
gastroesophageal reflux), or had no TDM. Preterm neo-
nates with abnormalities in central nervous system were
also excluded as the disease may affect the patient re-
sponse to caffeine. Patient demographics including gen-
der, birth weight, APGAR 1 min score, APGAR 5 min
score, GA, PNA at dosing or sampling, PMA at dosing
or sampling were recorded in enterprise data warehouse.
This study was reviewed, approved, and granted a waiver
of informed consent by the University of Utah Institu-
tional Review Board.
Sample collection and measurement
The information on doses, dosing intervals, and TDM
sample concentrations were obtained from enterprise
data warehouse of Intermountain Healthcare System. In
the clinical settings, a loading dose of either 40 mg/kg
(20 mg/kg caffeine base equivalent) or 20 mg/kg caffeine
citrate (10 mg/kg caffeine base equivalent) was adminis-
tered by intravenous infusion over 15 min, followed by a
maintenance dose of 5 mg/kg caffeine citrate (2.5 mg/kg
caffeine base equivalent) every 12 or 24 h through intra-
venous or orogastric/nasogastric routes. The dosing regi-
men is denoted as loading dose/maintenance dose,
dosing time interval throughout this paper. Decisions re-
garding caffeine citrate dosing regimen, use of TDM,
and timing of blood sample acquisition were made by
the clinical staff. The indication for TDM was inad-
equate responses such as repeated or severe apnea des-
pite the continuation of caffeine therapy or symptoms of
adverse events [13, 14]. The timing of sample collection
post last dose was random and was at the discretion of
the care providers. Total caffeine concentrations in
serum were measured by quantitative enzyme multiplied
immunoassay (EMIT caffeine assays, Siemens Health-
care, Pennsylvania, USA). The assay was accurate be-
tween 1 and 30 mg/L with between-day and within-day
imprecision < 10 % across this range [15]. Samples with
caffeine concentration > 30 mg/L were diluted in drug-
free serum and reanalyzed.
Clinical records identification and analysis
Intermountain HELP2 Clinical Desktop was searched to
obtain clinical notes concurrent with sample collections
using the patient’s enterprise master patient index num-
ber. The clinical notes included relevant critical care
progress notes or discharge summaries. Vital signs (heart
rate and respiratory rate) were recorded in the critical
care progress notes on the date of sample collection
along with the frequency of apnea and any adverse
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effects attributed to caffeine. The normal range of heart
rate in neonates is 120 – 160 beats per minute (b · min
−1) with toxicity associated with > 220 b · min−1. Episodes
of heart rate > 170 b · min−1 were considered as tachycar-
dia according to the clinical notes. The respiratory rate
normal range in neonates is 30 – 60 breaths per minute
(br · min−1) with toxicity defined as tachypnea > 80 br ·
min−1. Information on apnea or adverse events was
screened in the notes. Apnea was cessation of breathing
lasting > 20 seconds, and/or those that were shorter, but
associated with hypoxia (oxygen saturation < 85 %) or
bradycardia (heart rate < 100 b · min−1). Episodes of
apnea (number) or onset of adverse events (yes/no) that
happened on the same day of sample collection were re-
corded. If critical care progress notes concurrent with
sample collections were not available, the apnea or ad-
verse event records from the hospital discharge sum-
mary were searched to identify any information on
apneic episodes or adverse events on the date of sample
collection. Records from patients who were not on
mechanical ventilators on the days of TDM were used to
evaluate the relationships between vital signs/apnea epi-
sodes and caffeine serum concentrations. It is to note
that vital signs were measured during the physical exam
on the same day of TDM as dictated by the attending
clinician, thus may not reflect the heart rate in a tachy-
cardia event or respiratory rate in an apneic episode.
Clinical intervention in terms of endotracheal re-
intubation was used as a surrogate marker of treatment
failure in this study. Patients requiring endotracheal re-
intubation during the entire course of caffeine citrate
therapy were identified in the clinical notes. The under-
lying indications for re-intubation were divided into two
subgroups, one subgroup was re-intubation secondary to
worsening symptoms of apnea of prematurity, the other
subgroup was re-intubation secondary to other respira-
tory failure etiologies, such as significant periodic
breathing, increased work of breathing, increased CO2
levels, significant episodes of bradycardia with desatura-
tions, pleural effusions, pulmonary edema, and sus-
pected infections (no culture confirmation).
Statistics
Differences in caffeine serum concentrations between
dosing regimen groups were determined by Mann–
Whitney U test. Linear regression was used to evaluate
the association between PD effects and caffeine serum
concentrations. The relationships between treatment ef-
ficacy and patient demographics were also evaluated by
linear regression. Predicted probabilities for adverse
events as a function of caffeine serum concentrations
were assessed by logistic regression analysis. The num-
ber of patients requiring re-intubation or experiencing
adverse events was compared among various dosing
regimens via a χ2 test of independence. Statistics were
performed using SAS software (version 9.3) (SAS Inc.
North Carolina, USA) and differences were considered
significant at p < 0.05.
Results
A total of 115 preterm neonates who received caffeine
citrate therapy and underwent TDM in the post-
extubation period were included in this study. A total of
177 blood samples were taken from these patients with a
median (interquartile range) GA of 29 (28 – 30) weeks
and birth weight of 1230 (997 – 1485) g (Table 1). Caf-
feine citrate therapy was started in patients at PNA of 1
(1 – 3) day or PMA of 29.4 (28.1 – 30.7) weeks. Blood
samples were taken in patients with PNA of 15 (10 –
24) days or PMA of 31.6 (30.1 – 33.4) weeks (Table 1).
Patients had a median of one sample taken for TDM. As
shown in Table 2, 47 (40.9 %) patients received 40/5 mg/
kg q12h regimen, 49 (42.6 %) patients received 20/5 mg/
kg q24h. The dosing regimen of 40/5 mg/kg q12h led to
significantly higher concentrations compared with the
standard regimen 20/5 mg/kg q24h (median 23 vs
15 mg/L, p < 0.001). Patient demographics and clinical
statuses were similar among dosing regimen groups
(data not shown).
Out of 177 concentrations collected, 149 (84.2 %) con-
centrations had concurrent clinical notes that provided
relevant PD information. Among the 149 concentrations,
125 (83.8 %) concentrations had concurrent heart rate
and respiratory rate available in non-ventilated neonates,
whereas 89 (59.7 %) concentrations had corresponding
definitive number of apneic episodes recorded in non-
ventilated neonates. Linear regression analysis on heart
rate, respiratory rate, and episodes of apnea as a function
of caffeine serum concentrations showed that heart rate
was significantly associated with concentration (p < 0.05)
(Fig. 1a). Although this relationship was statistically sig-
nificant, the physiological effect was considered small
Table 1 Demographics of preterm neonates included in this
study
Characteristics Median (Interquartile range) Range
Sexa 60 male, 55 female
GA (week) 29 (28 – 30) 24–33
Birth weight (g) 1230 (997–1485) 607–2304
Apgar score, 1 min 6 (4–8) 1–9
Apgar score, 5 min 8 (7–9) 3–9
PNA at initiation (day) 1 (1–3) 0–25
PMA at initiation (week) 29.4 (28.1–30.7) 24.1–33.6
PNA at sampling (day) 15 (10–24) 3–84
PMA at sampling (week) 31.6 (30.1–33.4) 25.6–40.9
aNumber
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potentially due to the fact that retrospective records
were used. The median (range) of heart rates at caffeine
serum concentration of 5–10 mg/L and 30–35 mg/L
were 160 (130–183) and 168 (151–175) b · min−1, re-
spectively. No linear relationships were found for the
other PD parameters (Fig. 1b, c). The relations between
apnea episodes in the day and patient demographics
were assessed. It was found that there was an inverse re-
lationship between number of apnea episodes in the day
and GA of neonates (p < 0.05) (Fig. 2a). Frequency of
apnea episodes decreased significantly as PMA increased
(p < 0.05) (Fig. 2b).
The most common adverse event during caffeine
TDM was tachycardia. Out of 149 concentrations with
concurrent medical records documented, there were 34
(22.8 %) concentrations associated with tachycardia, 3
(2.0 %) with tachypnea, and 1 (0.7 %) with mild hyper-
tension, which were considered to be secondary to caf-
feine citrate therapy. The severity of recorded
tachycardia was mostly mild to moderate with heart rate
ranging from 170 – 212 b · min−1 amid an episode. The
frequency of tachycardia or the percentage of samples
with tachycardia relative to the concentration was plot-
ted in Fig. 3. Predicted probabilities for tachycardia
events as a function of caffeine serum concentrations
were also shown in Fig. 4.
Out of 115 patients, a total of 27 patients (23.4 %)
were re-intubated onto a mechanical ventilator during
the entire course of caffeine citrate therapy, of which 10
patients (8.6 %) were re-intubated secondary to
worsening symptoms of apnea. As shown in Table 3,
there was no difference in re-intubation rate secondary
to apnea of prematurity or other pulmonary etiologies
between regimen 40/5 mg/kg q12h and standard 20/
5 mg/kg q24h, however, regimen 40/5 mg/kg q12h led
to significantly higher percentage of patients experien-
cing tachycardia than the standard regimen (p < 0.001).
Patients going through re-intubation tend to be more
preterm [mean (range) GA 27 (24–31) weeks] with
less birth weight [963 (607 – 1892) g] than average
statistics of this study population (Table 1). There
was no difference in these patients’ demographics
among dosing regimens (Additional file 1: Table S1).
Table 2 Caffeine citrate dosing regimens and caffeine serum
concentrations during TDM
Dosing regimens Number of patients Caffeine serum
concentration (mg/L)
40/5 mg/kg
q12h 47 23 (18–26)***
20/5 mg/kg
q24h 49 15 (11–17)
q12h 8 17 (13–20)
5/5 mg/kg
q24h 6 13 (8–17)
q12h 5 22 (21–23)
Data =median (interquartile range)
***p < 0.001, significant differences were observed in caffeine serum
concentrations between regimen 40/5 mg/kg q12h and standard 20/5 mg/kg
q24h
Fig. 1 Relation of a heart rate (r2 = 0.031, p = 0.04), b respiratory rate (r2 = 0.001, p = 0.68), c episodes of apnea (r2 < 0.001, p = 0.97) recorded
during the physical exam in the day of TDM as a function of caffeine serum concentration. Note: b · min−1, beats per minute; br · min−1, breaths
per minute
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Discussion
The present study revealed that a correlation between
number of apneic episodes and caffeine serum concen-
trations was not established under current dosing regi-
mens. A significant association between heart rate and
concentrations was found among the other PD parame-
ters, consistent with the fact that the probability of
tachycardia increased as caffeine serum concentration
increased. A high dose regimen 40/5 mg/kg q12h led to
similar re-intubation rate but significantly higher per-
centage of patients having tachycardia than standard
regimen 20/5 mg/kg q24h, agreeing well with the PK/PD
relationships found above. The total re-intubation rate
of the standard regimen in our patients (24.5 %) was
similar to that reported in the literature (24.0 %) [16].
The lack of correlation between efficacy and caffeine
serum concentrations under current dosing regimens was
in agreement with the trial that granted caffeine citrate label
approval by FDA, which reported no association between
success of ≥ 50 % reduction or elimination in apnea events
and mean daily caffeine concentrations.3 Skouroliakou
et al.’s study also revealed that methylxanthine concentra-
tions were not significantly associated with number of
apneic events per day in neonates with GA< 33 weeks [17].
A previous study comparing 10 mg/kg and 5 mg/kg main-
tenance doses in neonates with GA< 32 weeks showed
similar efficacy in reducing apnea spells despite signifi-
cantly higher frequency of tachycardia in the 10 mg/
kg group [18]. It could be partially due to the under-
lying multifactorial etiology of apnea, with prematur-
ity being a prerequisite for the indication [19]. Apnea
of prematurity is known to have an incidence in-
versely related to GA and could regress with the mat-
uration of the newborn [19]. This is echoed in our
results that the number of apnea episodes reduced
significantly as PMA increased as well as in patients
with higher GA (Fig. 2).
The variable PK/PD response in neonates to caffeine cit-
rate therapy is also likely to be attributed to variability in
caffeine metabolism in individuals. Caffeine metabolism by
hepatic enzymes is usually limited in neonates. Maturation
of metabolic enzymes could lead to the improvement in
metabolic function, which is significantly associated with
the increase in PNA and varies extensively among individ-
uals (range 1 %–41 %) [20]. N7-demethylation, which pro-
duces theophylline, acts as the predominant metabolic
pathway in premature neonates (range 1 %–37 %) [20].
Theophylline is the active metabolite that is partially re-
sponsible for side effects such as tachycardia [18], the vari-
able caffeine-theophylline conversion rate could lead to PD
response variability. Several other factors, including genetic
variation in hepatic metabolic enzymes and genetic varia-
tions in caffeine receptors may also contribute to the vari-
ability in PD responses [21–23]. Due to the variability in
the caffeine metabolism and the resulting wide range of
half-lives among individuals [10], the measurement of caf-
feine serum concentrations at a postnatal age of 15 (10–24)
days in our study population may not necessarily reflect
concentrations at steady state. Thus, caffeine concentra-
tions may vary considerably and make it difficult to find
other significant associations between PD responses and
concentrations.
The 2-fold higher-than-standard dosing regimen led to
similar re-intubation rate but significantly higher
Fig. 2 Number of apnea episodes in the day of TDM as a function of a GA (r2 = 0.061, p = 0.01), b PMA (r2 = 0.071, p = 0.01) in preterm neonates
Fig. 3 The frequency of tachycardia or the percentage of samples
with tachycardia relative to caffeine serum concentration in
preterm neonates
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percentage of patients having tachycardia than standard
regimen. This is similar to Steer et al.’s findings on the use
of 3–6 fold higher maintenance doses for a course of
7 days in neonates of similar GA range (<32 weeks) to our
study’s (<33 weeks) [24]. A significant reduction in re-
ventilation was shown when 4-fold higher maintenance
doses were used for the duration of averagely 1 month in
neonates with GA < 30 weeks [16]. This effect was more
evident in the stratified subgroup of neonates with GA <
28 weeks that a significant reduction in the days on
mechanical ventilator (average 8 days) was observed [16]. A
retrospective study in neonates < 28 weeks GA revealed
that patients receiving caffeine citrate > 7.9 mg/kg/day were
associated with a decreased need for clinical interventions
in terms of dose adjustments compared to those receiving ≤
7.9 mg/kg/day doses [25]. It suggests that neonates with
lower GA, especially extremely low-gestational-age neo-
nates (GA < 28 weeks), could benefit more from high doses
of caffeine citrate. Dosing regimens stratified by GA is war-
ranted for more systematic trial evaluation.
None of the neonates died or had a severe reaction under
current dosing regimens, however, TDM may be helpful in
suspected toxicity to diagnose caffeine-related adverse
events, based on our findings on a significant association
between tachycardia and caffeine serum concentrations.
The use of high dose caffeine citrate inevitably increases
the risk of tachycardia in neonates, this need to be taken
into consideration combined with other elements of ther-
apy, such as efficacy and requirement for respiratory sup-
port, to determine treatment priority in lieu of medical cost
and facility resources available. Caffeine TDM is valuable in
the setting of clinically-significant tachycardia to assist dif-
ferential diagnosis with respect to other potential etiologies.
This study has several limitations associated with its na-
ture of retrospective chart evaluation. First, the TDM was
done at the discretion of the medical team and may have
patient selection bias towards sicker patients or patients
who had adverse events. Second, vital signs were measured
during the physical exam in the day of TDM, thus, they
Fig. 4 Predicted probabilities of tachycardia as a function of caffeine serum concentration in preterm neonates. An open circle represents the
presence (probability = 1) or absence (probability = 0) of a tachycardia event at the corresponding concentration. The solid line with blue band
represents estimated probability and the 95 % confidence limits
Table 3 Summary of clinical interventions/adverse events in
terms of re-intubation and tachycardia among dosing regimens
Dosing
regimens
Number of patients going
through re-intubation (%)
Number of patients
having tachycardia (%)
Secondary
to apnea of
prematurity
Secondary to
other respiratory
etiologies
40/5 mg/kg
q12h 4 (8.5 %) 7 (14.9 %) 21*** (44.7 %)
20/5 mg/kg
q24h 4 (8.2 %) 8 (16.3 %) 5 (10.2 %)
q12h 0 1 (12.5 %) 4 (50.0 %)
5/5 mg/kg
q24h 2 (33.3 %) 0 1 (16.7 %)
q12h 0 1 (20.0 %) 0
***p < 0.001, regimen 40/5 mg/kg q12h led to significantly higher percentage
of patients experiencing tachycardia secondary to caffeine citrate therapy than
standard 20/5 mg/kg q24h
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were the approximate rather than the exact values at TDM
sampling time. Third, the records were physician notes that
were not verified by audits of electronic monitoring, how-
ever, they are the critical information used by clinicians for
patient management and decision making.
Conclusion
Based on our analysis on the retrospective dataset, little
correlation between episodes of apnea and caffeine serum
concentrations was observed in neonates who had TDM in
the post-extubation period under current dosing regimens,
whereas a significant association between tachycardia and
concentrations existed. Notwithstanding the absence of se-
vere adverse reactions, TDM should be considered in critic-
ally ill neonates with unexplained adverse effects, such as
tachycardia. Future prospective study is warranted to estab-
lish the linked PK/PD relationship to optimize dosing regi-
men in preterm neonates.
Availability of supporting data
Supporting data are available in the form of an extended
study report to the ethics committee of the University of
Utah Institutional Review Board. This report is available
upon request, which should be addressed to the corre-
sponding author.
Additional file
Additional file 1: Table S1 Demographics of preterm neonates stratified
by major dosing groups (DOCX 14 kb)
Abbreviations
GA: gestational age; PD: pharmacodynamics; PK: pharmacokinetics;
PMA: post-menstrual age; PNA: post-natal age; TDM: therapeutic drug
monitoring.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CS and RW developed the idea for this study, KK extracted data for this
study, TY did the study design, completed the data analysis, and wrote the
manuscript, AB assisted with statistical analysis, RW provided clinical
consultation on this work. All authors reviewed the manuscript, provided
critical feedback, and approved its journal submission.
Acknowledgements
This project was supported in part by a Primary Children’s Hospital
Foundation Early Career Development Research Grant for Catherine M. T.
Sherwin. Authors would like to thank Chris R. Stockmann for assistance with
clinical note information.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/
1.0/) applies to the data made available in this article, unless otherwise
stated.
Author details
1Division of Clinical Pharmacology, School of Medicine, University of Utah,
295 Chipeta Way, Suite 1C310, Salt Lake City, UT 84108, USA. 2Division of
Neonatology, Department of Pediatrics, School of Medicine, University of
Utah, Salt Lake City, Utah 84108, USA. 3Intermountain Healthcare, Salt Lake
City, Utah 84108, USA.
Received: 7 November 2015 Accepted: 29 April 2016
References
1. Bhatt-Mehta V, Schumacher RE. Treatment of apnea of prematurity. Paediatr
Drugs. 2003;5:195–210.
2. Schoen K, Yu T, Stockmann C, Spigarelli MG, Sherwin CM. Use of
methylxanthine therapies for the treatment and prevention of apnea of
prematurity. Paediatr Drugs. 2014;16:169–77.
3. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine
citrate for the treatment of apnea of prematurity: a double-blind, placebo-
controlled study. Pharmacotherapy. 2000;20:644–52.
4. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in
treatment of apnea in the low-birth-weight infant. J Pediatr. 1977;90:467–72.
5. Kulkarni PB, Dorand RD. Caffeine toxicity in a neonate. Pediatrics. 1979;64:
254–5.
6. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al.
Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–21.
7. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al.
Long-term effects of caffeine therapy for apnea of prematurity. N Engl J
Med. 2007;357:1893–902.
8. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring
for caffeine in preterm neonates: an unnecessary exercise? Pediatrics. 2007;
119:936–40.
9. Leon AE, Michienzi K, Ma CX, Hutchison AA. Serum caffeine concentrations
in preterm neonates. Am J Perinatol. 2007;24:39–47.
10. Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A.
Caffeine citrate treatment for extremely premature infants with apnea:
population pharmacokinetics, absolute bioavailability, and implications for
therapeutic drug monitoring. Ther Drug Monit. 2008;30:709–16.
11. Gal P. Caffeine Therapeutic Drug Monitoring Is Necessary and Cost-effective.
J Pediatr Pharmacol Ther. 2007;12:212–5.
12. Gal P. Optimum use of therapeutic drug monitoring and
pharmacokinetics-pharmacodynamics in the NICU. J Pediatr Pharmacol
Ther. 2009;14:66–74.
13. Ward RM, Lugo RA. Drug therapy in the newborn. In: MacDonald MG,
Seshia MMK, Mullett MD, editors. Avery’s neonatology: pathophysiology &
management of the newborn. 6th ed. Philadelphia PA: Lippincott Williams
& Wilkins; 2005. p. 1507–56.
14. Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring.
Clin Pharmacol Ther. 1988;43:345–53.
15. Pesce AJ, Rashkin M, Kotagal U. Standards of laboratory practice:
theophylline and caffeine monitoring. National Academy of Clinical
Biochemistry. Clin Chem. 1998;44:1124–8.
16. Steer P, Flenady V, Shearman A, Charles B, Gray PH, Henderson-Smart
D, et al. High dose caffeine citrate for extubation of preterm infants: a
randomised controlled trial. Arch Dis Child. Fetal Neonatal Ed. 2004;89:
499–503.
17. Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline
for apnea of prematurity: a randomised controlled trial. J Paediatr Child
Health. 2009;45:587–92.
18. Romagnoli C, De Carolis MP, Muzii U, Zecca E, Tortorolo G, Chiarotti M, et al.
Effectiveness and side effects of two different doses of caffeine in
preventing apnea in premature infants. Ther Drug Monit. 1992;14:14–9.
19. Paolillo P, Picone S. Apnea of prematurity. J Pediatr Neonatal Individ Med.
2013;2:1–7.
20. Al-Alaiyan S, Al-Rawithi S, Raines D, Yusuf A, Legayada E, Shoukri MM, et al.
Caffeine metabolism in premature infants. J Clin Pharmacol. 2001;41:620–7.
21. Bloch-Salisbury E, Hall MH, Sharma P, Boyd T, Bednarek F, Paydarfar D.
Heritability of apnea of prematurity: a retrospective twin study. Pediatrics.
2010;126:779–87.
22. Kumral A, Tuzun F, Yesilirmak DC, Duman N, Ozkan H. Genetic basis of
apnoea of prematurity and caffeine treatment response: role of adenosine
Yu et al. BMC Pharmacology and Toxicology  (2016) 17:22 Page 7 of 8
receptor polymorphisms: genetic basis of apnoea of prematurity. Acta
Paediatr. 2012;101:299–303.
23. Pacifici GM. Clinical pharmacology of caffeine citrate in preterm infants.
Med expr. 2014;1:243–50.
24. Steer PA, Flenady VJ, Shearman A, Lee TC, Tudehope DI, Charles BG.
Periextubation caffeine in preterm neonates: a randomized dose response
trial. J Paediatr Child Health. 2003;39:511–5.
25. Francart SJ, Allen MK, Stegall-Zanation J. Apnea of prematurity: caffeine
dose optimization. J Pediatr Pharmacol Ther. 2013;18:45–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yu et al. BMC Pharmacology and Toxicology  (2016) 17:22 Page 8 of 8
